Helios Inhibitor Compounds for Stable Treg Differentiation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current strategies fail to effectively target Helios protein for modulating regulatory T-cell (Treg) differentiation and function, particularly in the tumor microenvironment, leading to instability and conversion into effector T cells, which impedes antitumor immune responses and exacerbates chronic viral infections.

Innovation Solution

Development of compounds that inhibit Helios protein by interacting with the Cullin4-Cereblon E3 ubiquitin ligase complex, reducing Helios levels and activity to control Treg differentiation and stabilize their suppressive phenotype.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current strategies are used to target Helios protein, then Treg differentiation can be modulated, but Treg stability deteriorates and conversion into effector T cells occurs

Engineering Contradiction:

ImproveTreg stabilityVSAvoidconversion into effector T cells

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent introduces compounds as intermediary substances that specifically interact with the Cullin4-Cereblon E3 ubiquitin ligase complex to modulate Helios protein levels. These compounds act as mediators between the therapeutic goal (controlling Treg differentiation) and the molecular target (Helios protein), enabling precise control of Treg stability without causing unwanted conversion to effector T cells.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent employs compounds that induce parameter changes in the Helios protein system by altering its ubiquitination status and degradation rate. By changing the molecular parameters of Helios (stability, concentration, activity), the treatment achieves enhanced Treg stability and prevents pathological conversion to effector T cells.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If Helios levels are reduced to control Treg differentiation, then Treg suppressive function is improved, but antitumor immune responses may be enhanced excessively

Engineering Contradiction:

ImproveTreg suppressive functionVSAvoidantitumor immune responses

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies partial action by using compounds that moderately reduce Helios protein levels rather than completely eliminating it. This partial reduction is sufficient to enhance Treg suppressive function and control Treg differentiation, while avoiding excessive suppression of antitumor immune responses. The dosing and compound design enable fine-tuned control of the therapeutic effect.

Inventive Principle:

Principle #16Partial or excessive action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

These compounds enhance Treg stability and suppressive function, promoting effective antitumor immune responses and improving cancer immunotherapy outcomes while minimizing autoimmune side effects.

Implementation Method 1

Development of compounds that inhibit Helios protein by interacting with the Cullin4-Cereblon E3 ubiquitin ligase complex, reducing Helios levels and activity

Methodology Applied

Scientific EffectUbiquitin ligase complex:

Data Source

PatentEP4061812B1Compounds useful as inhibitors of helios protein

Publication Date: 2026.03.25 BRISTOL MYERS SQUIBB CO

AI summary

Disclosed are compounds of Formula (I) or a salt thereof, wherein Z is CR6R6 or C=O; Ring A is, and R1, R2, R3, R4, R5, m, and n are defined herein. Also disclosed are methods of using such compounds to inhibit Helios protein, and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.